With Wyeth Merger In Beijing's Hands, Pfizer CEO Tours China To Launch Scholarly Partnerships
This article was originally published in The Pink Sheet Daily
Executive Summary
Just days after revealing that the Ministry of Commerce has delayed a decision on approval of the Pfizer-Wyeth merger, Kindler touched down in China to meet with government officials and launch the $1.5 million initiative.
You may also be interested in...
68 Billon Dollar Question: Could China's Government Block Worldwide Merger Of Wyeth And Pfizer?
BEIJING - Tucked away toward the end of the $68-billion merger agreement between Pfizer Inc. and Wyeth is a clause that could give the Chinese government the ultimate power to approve or block this worldwide union of American pharmaceutical giants
Global Pharma Giants Concered About China’s New Anti-Monopoly Law
BEIJING - Leading executives at multinational firms operating in China, including some pharmaceutical giants, are concerned that the country's new anti-monopoly law could be used to counter strong market positions or to forced licensing of innovative products to competitors
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.